Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00934180 · ClinicalTrials.gov registry record · Phase 1

Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions

A Phase 1 study, sponsored by Teva Pharmaceuticals USA.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT00934180: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.

NCT00934180 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00934180, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

The objective of this study was to compare the relative bioavailability of the test formulation of Ondansetron HCl with the already marketed reference formulation Zofran ODT under fasting conditions in healthy, non-smoking adult subjects.

Primary Outcome

Bioequivalence based on Cmax

Interventions

  • DRUG Ondansetron
  • DRUG Zofran®

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2002-12
Est. Completion 2002-12
Phase Phase 1
Teva Pharmaceuticals USA

83 total trials

What the finished NCT00934180 record still lists

NCT00934180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).

The record links to 0 conditions, and to 2 interventions - of which Ondansetron is the first listed.

NCT00934180 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00934180 about?

NCT00934180 is a clinical study titled "Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions". The objective of this study was to compare the relative bioavailability of the test formulation of Ondansetron HCl with the already marketed reference formulation Zofran ODT under fasting conditions in healthy, non-smoking adult subjects.

What is the current status of trial NCT00934180?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2002-12. Estimated completion is 2002-12.

What interventions are being tested in trial NCT00934180?

The interventions under investigation include: Ondansetron (DRUG), Zofran® (DRUG).

Who is sponsoring clinical trial NCT00934180?

This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00934180's enrollment target sits among peer trials

24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00934180, the US trial registry maintained by the National Library of Medicine. NCT00934180 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.